DNAprint Genomics (DNAG)

[johnnyfiber]

JUST A LITTLE INTERESTING:

10-K 1 d10k.htm FORM 10-K FOR SEQUENOM, INC

Products and Applications

Our MassARRAY system provides reliable results for numerous types of DNA analysis applications including SNP genotyping and allelotyping, SNP discovery, quantitative gene expression analysis, quantitative methylation marker analysis, and oligonucleotide quality control. While the MassARRAY system is versatile, it also became a more cost-effective solution for customer needs with our 2005 launch of the iPLEX assay. The iPLEX assay is a proprietary assay, which provides for multiplexed DNA sample analysis that in turn provides cost-effectiveness by allowing the user to perform multiple sample analyses using a similar amount of reagents


As of March 15, 2006, there were 40,249,748 shares of the Registrant’s Common Stock outstanding

Recent Development

On March 27, 2006, we entered into a securities purchase agreement with three investors that provides for the sale of common stock and warrants to purchase common stock to the investors for gross proceeds to us of $30.0 million not including any proceeds from exercise of the warrants.

On March 30, 2006, we amended and restated the securities purchase agreement to add a fourth investor and increase the gross proceeds to $33.0 million not including proceeds from exercise of the warrants. Under the amended and restated securities purchase agreement, we will issue to the investors, subject to the approval of our stockholders and the satisfaction of various closing conditions, (i) an aggregate of 60,000,000 shares of our common stock and (ii) seven-year warrants to purchase an aggregate of 36,000,000 shares of our common stock at an exercise price of $0.70 per share (subject to certain antidilution protections and other adjustment provisions]

We have a history of recurring losses from operations and have an accumulated deficit of $442.6 million as of December 31, 2005. Our capital requirements to sustain operations, including research and development projects, have been and will continue to be significant. As of December 31, 2005, we had available cash and short-term investments totaling $6.0 million and working capital of $5.4 million

I took this info from their 10k from 2005

http://www.sec.gov/Archives/edgar/data/1076481/000119312506070581/d10k.htm#toc88263_10

Their stock is trading at $4. Outstanding, if diluted about 140 million.

Accumulated deficit $443 million

Compare that to DNAG #'s

price: .0175

Outstanding, if diluted about 600 million

Accumulated deficit: $38 million? I think.

SQNM chart
http://www.moqvo.com/en/bioserve__bioserve_unveils_new_dna_methylation_service_4887356.html

The reason I looked at this company is because their technology is very similiar. And also because:

BioServe Unveils New DNA Methylation Service
LAUREL, MD -- (MARKET WIRE) -- December 11, 2006 -- BioServe Biotechnologies, a leader for fast, economical processing and analyses of genomic content from biological samples, today introduced its new DNA Methylation Analysis Service using Sequenom, Inc.'s (NASDAQ: SQNM) MassARRAY® System and EpiTYPER™ methodology.

http://www.moqvo.com/en/bioserve__bioserve_unveils_new_dna_methylation_service_4887356.html

AND THIS:[/B]

BioServe Signs Distribution Deal With Merck Specialties Private Limited

LAUREL, MD -- (MARKET WIRE) -- January 09, 2007 -- BioServe Biotechnologies, the leader for fast, economical processing and analyses of genomic content from biological samples, today announced a distribution deal with Merck Specialties Private Limited (MSPL), 100% Indian subsidiary of Merck KgaA. Under terms of the contract, MSPL will market and distribute BioServe's genomic products and services, including DNA and RNA purification reagents, DNA sequencing, oligonucleotide synthesis and molecular biology teaching kits in India, with plans to extend distribution coverage across Asia in 2007.

http://www.moqvo.com/en/bioserve__bioserve_signs_distribution_deal_with_merck_specialties_private_li...